Although intensive plasma glucose control with sulfonylureas or insulin does not reduce macrovascular disease [31], pioglitazone reduces the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with DM [32]. This evidence concerns the gene INS and diabetes mellitus.